References

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)

10.1093/ehjci/jeac106 · 2022 · External reference

Venous thromboembolism in cancer patients: a population-based cohort study

10.1182/blood.2020007338 · 2021 · External reference

Incidence of venous thromboembolism in patients with cancer – a cohort study using linked United Kingdom databases

10.1016/j.ejca.2012.10.021 · 2013 · External reference

Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients

10.1002/cncr.23062 · 2007 · External reference

Bleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort study

10.1182/blood.2024025362 · 2024 · External reference

Extended reduced-dose apixaban for cancer-associated venous thromboembolism

10.1056/nejmoa2416112 · 2025 · External reference

Splenomegaly - diagnostic validity, work-up, and underlying causes

10.1371/journal.pone.0186674 · 2017 · External reference

Spleen size is significantly influenced by body height and sex: establishment of normal values for spleen size at US with a cohort of 1200 healthy individuals

10.1148/radiol.2015150887 · 2016 · External reference

Incidentally detected splenomegaly and risk of hematologic cancer and liver disease

10.1001/jamaoncol.2025.5934 · 2026 · External reference

Overlapping and non-overlapping indications for checkpoint inhibitors in the US

10.1200/jco.2024.42.16_suppl.11057 · 2024 · External reference

Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs

10.1001/jamanetworkopen.2020.0423 · 2020 · External reference

Temporal trends and outcomes among patients admitted for immune-related adverse events: a single-center retrospective cohort study from 2011 to 2018

10.1002/onco.13740 · 2021 · External reference

Immune checkpoint inhibitor–associated cardiovascular toxic effects: International Cardio-Oncology Society position statement

10.1001/jamaoncol.2025.4543 · 2026 · External reference

Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis

10.1001/jamaoncol.2024.3065 · 2024 · External reference

Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis

10.1001/jamaoncol.2018.3923 · 2018 · External reference

Association among major adverse cardiovascular events with immune checkpoint inhibitors: a systematic review and meta-analysis

10.1111/joim.20028 · 2025 · External reference

Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement

10.1093/eurheartj/ehab674 · 2022 · External reference

Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis

10.1136/jitc-2020-001887 · 2020 · External reference